Lewis y/b Hapten antibody

Catalog No. ABIN5564290

The Mouse Monoclonal anti-Lewis y/b Hapten antibody (Clone SC104) (ABIN5564290) specifically detects Lewis y/b Hapten in ELISA, FACS, Func, ICC and IHC. The antibody is reactive with Human samples.

Quick Overview for Lewis y/b Hapten antibody (ABIN5564290)

Target: Lewis y/b Hapten

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Application: ELISA, Flow Cytometry (FACS), Functional Studies (Func), Immunocytochemistry (ICC), Immunohistochemistry (IHC)

Clone: SC104

Product Details

Specificity: Recognizes human sialyltetraosylceramide. Does not bind to blood lympocytes, granulocytes, bone marrow progenitor cells, GM1, GD1a, GT1b or sialyl LewisX antigens.

Cross-Reactivity: Human

Purity: >95 % (SDS-PAGE)

Endotoxin Level: <0.001EU/μg purified protein (LAL test, Lonza).

Immunogen: Tissue cultured colorectal tumor cell lines (C170, C146, Colo205 and JW).

Isotype: IgG1

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: In PBS.

Preservative: Without preservative

Storage: 4 °C,-20 °C

Storage Comment: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C.

Expiry Date: 12 months

Target Details

Target: Lewis y/b Hapten

Alternative Name: Lewisy/b hapten

Background: Membrane glycolipids represent an unexplored source of tumor-associated antigens. Many of these are overexpressed and altered in tumors compared to normal tissue. Research into aberrant glycosylation and over-expression of glycolipids on the surface of the majority of cancers, coupled with a knowledge of glycolipids as functional molecules involved in a number of cellular physiological pathways, has provided a novel area of targets for cancer immunotherapy. Lewis-y/b is a cell surface carbohydrate blood group antigen expressed at very low levels in normal tissue, but often found to be overexpressed on breast, lung, colon and ovarian cancer cells. Clone SC104 recognizes a unique cell surface antigen sialyltetraosylceramide, expressed by 90 % of colorectal tumors at all clinical stages. SC104 targets colorectal cancer-associated glycolipids and induces tumor cell death in vitro independently of CDC or ADCC or blockade of known survival signaling pathways. It induces apoptotic cell death and synergizes with chemotherapy in vivo in mice.